Karolinska Development's Modus Therapeutics Gets Approval For 2nd Part Of Phase 2 Study

RefinitivMenos de 1 minuto de leitura

Karolinska Development AB KDEV:

REG-KAROLINSKA DEVELOPMENT'S PORTFOLIO COMPANY MODUS THERAPEUTICS RECEIVES APPROVAL FOR SECOND PART OF PHASE 2 STUDY IN CHRONIC KIDNEY DISEASE WITH ANEMIA

© Copyright Thomson Reuters 2025. Click For Restrictions - https://agency.reuters.com/en/copyright.html

Entrar ou criar uma conta gratuita para ler essa notícia